Press Release. CSIR launches ayurvedic anti-diabetic drug BGR-34

Updated - January 18, 2018 at 12:05 AM.

Business Wire India

Developed jointly by NBRI & CIMAP, research units of CSIR
Scientifically validated for its efficacy and safety
Price only Rs 5/- per Tablet

Dr.A.K.S. Rawat, Sr. PrincipalScientist of CSIR-NBRIBerberis aristataTinospora cordifoliaPterocarpus marsupiumGymnema SylvestreRubia cordifoilaTrigonella foenum-graecumDr Daya Nandan Mani, Senior Scientist of CSIR-NBRIMr. Pankaj Marwaha, Marketing Director of AIMIL Pharmaceuticals (India) LtdDr Anil Kumar Sharma Vice President (Technical) of AIMIL Pharmaceuticals (India) Ltd,Photo Caption:

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.

Sign into Unlock benefits!

Access 10 free stories per month
Access to comment on every story
Sign up/Manage to our newsletters
Get notified by email for early preview to new features, discounts & offers

Press Release. CSIR launches ayurvedic anti-diabetic drug BGR-34

You might also like

You might also like

Comments